Representational image of medicines | Photo: Manisha Mondal | ThePrint
Representational image | Photo: Manisha Mondal | ThePrint
Text Size:

New Delhi: The US Food and Drug Administration (FDA) Thursday warned against consumption of top-selling drugs — gabapentin and pregabalin that are sold in India to treat neurological disorders — as they may cause “serious breathing difficulties”. 

These drugs are commonly known as “gabapentinoids” drugs.

Approved for a variety of conditions, including seizures, nerve pain from spinal cord injury, shingles and restless legs syndrome — gabapentinoids are sold by several top companies in India, including Pfizer, Sun Pharma, Torrent Pharmaceuticals, Cipla, Lupin and Cadila Pharmaceuticals.

“The FDA is warning that serious breathing difficulties may occur in patients using gabapentin or pregabalin, who have respiratory risk factors,” the FDA said in a statement.

The American health regulator also said if patients suffering from chronic obstructive pulmonary disease (COPD) take gabapentinoids drugs along with opioid pain medicines, then it may harm their central nervous system. 

“The elderly are also at a higher risk,” the FDA added. 

Gabapentinoids are commonly prescribed by neurologists in India, especially to treat back or nerve pain.  

We are deeply grateful to our readers & viewers for their time, trust and subscriptions.

Quality journalism is expensive and needs readers to pay for it. Your support will define our work and ThePrint’s future.

SUBSCRIBE NOW

“Over 33 per cent of my patients are either on gabapentin and pregabalin. The profile of both drugs is almost the same with no major difference and both are equally popular with all neurosurgeons. Generally, it is prescribed to people suffering from some kind of back or nerve pain, which radiates towards legs or arms,” said Dr Rahul Gupta, a neurologist at Fortis Hospital in Noida.


Also read: Torrent Pharma warned by US again, this time for using bacteria-contaminated water system


Growing sales of drugs in India 

Fairly old in the Indian market, gabapentin was first approved in 1993 and pregabalin in 2004.

These drugs, which are sold under the brand names of Lyrica, Lyrica CR, Pregeb, Gabacip and Gabantin, have registered a sale of over Rs 300 crore in India from January to November 2019, according to data by IQVIA, a health information company. In combination with other drugs, gabapentinoids recorded a sale of Rs 700 crore, the data showed.

Gabapentin and pregabalin registered sales worth Rs 97.1 crore and Rs 216.8 crore, respectively, until November 2019 — posting a decent increase of 25 per cent and 16 per cent from 2017 when the figures stood at Rs 77.9 crore and 187.7 crore.

Risks FDA noted

As many as 49 case reports were submitted to the FDA over a five-year period from 2012. These reports showed that 12 people died from “respiratory depression” arising from the use of gabapentinoids, according to the FDA.

Also tested on healthy individuals and animals, the trials showed that using pregabalin alone and using it with an opioid pain reliever can affect breathing function. “The other trial showed gabapentin alone increased pauses in breathing during sleep,” the FDA said.

Will study FDA warning in detail, then act, says India

Reacting to the FDA warning, a senior official of Indian drug quality regulator Central Drugs Standard Control Organisation said, “We will study the observations of US FDA in detail and act accordingly.” 

However, the US FDA has planned several actions.   

“We require new warnings about the risk of respiratory depression to be added to the prescribing information of the gabapentinoids.”

“We have also required the drug manufacturers to conduct clinical trials to further evaluate their abuse potential with opiods…Special attention will be paid to the respiratory depressant effects during this abuse potential evaluation,” it added.


Also read: Indians pay 70% less than the global median to buy medicines, study finds


 

Subscribe to our channels on YouTube & Telegram

News media is in a crisis & only you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And we aren’t even three yet.

At ThePrint, we invest in quality journalists. We pay them fairly and on time even in this difficult period. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is. Our stellar coronavirus coverage is a good example. You can check some of it here.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it. Because the advertising market is broken too.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous, and questioning journalism, please click on the link below. Your support will define our journalism, and ThePrint’s future. It will take just a few seconds of your time.

Support Our Journalism

5 Comments Share Your Views

5 COMMENTS

  1. The problem mentioned here is not primarily due to gabapentin or pregabalin, but due to opioids.
    This article is unnecessarily published without knowing prescribing practises in India.

  2. It’s an obvious standard practice of experimentation & then retrieval of the expenses incurred in the form of business management through poor, less literate, unprivileged,3rd,4th world countries of the globe by the so called 1st world countries,ultimately shrugging all off after retrieval & then jump for another business in the pretext of pharmaceutical upliftment/business to get the rest of the vagabonds drenched and floored under the ground.So,what is new in it? * You have to find your survival mode!👍

  3. Absolute fear mongering article. Most common use in India for gabapentinoids is diabetic neuropathy, also there are no opiod combinations available in India. Patients who are actually getting benefitted may stop using these drugs just because you posted something from the FDA. Do you know paracetamol can cause death? Why don’t you make an article on that?

  4. The title and tilt of the article is misleading. These are standard drugs, discovered and developed in the west, snd sold all over the world for decades. Side effects have been reported now and the FDA has paid heed to them. Hence the warning. Good that you report that. Your headline makes it seem that these drugs are exclusively used in India, or that the rest of the world has stopped using them. We will soon be bombarded by messages suggesting that Indian doctors are using drugs that are ‘banned’ in the West.
    An appropriate way to report this would have been to highlight the FDA decision, and add that these drugs are ALSO commonly used in India, like in all other countries across the world..

  5. The author of this article has not studied the full research article. I am a physician and I have read the article in full. The risk of respiratory depression is mostly in people who are concurrently taking opioids which are rarely used in India on OP basis and there are very tight controls enough to frighten Indian doctors from using them.
    Other risk factors such as COPD or elderly is already known to Indian doctors but the risk is nowhere as that of opioids. These drugs are a different class and far safer than using opioids.
    Please read the article completely and if you do not understand medical science, ask a proper doctor to read it completely and convey the meaning to you. Don’t use your own harebrained interpretation making every research article into an alarmist journalist article.

LEAVE A REPLY

Please enter your comment!
Please enter your name here